A Phase 1 Study of BMS-986360/CC-90001 Alone and in Combination with Chemotherapy or Nivolumab in Advanced Solid Tumors

2022-500930-27-00 Protocol IM043-004 Human pharmacology (Phase I) - Other Ended

Start 15 Sep 2023 · End 13 May 2025 · Status Ended · 3 EU/EEA countries · 11 sites · Protocol IM043-004

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 149
Countries 3
Sites 11

Solid Tumor

Key facts

Sponsor
Celgene Corp.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
15 Sep 2023 → 13 May 2025
Decision date (initial)
2023-07-17
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2022-500930-27-00
WHO UTN
U1111-1284-2839

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Solid Tumor

VersionLevelCodeTermSystem organ class
21.1 LLT 10065252 Solid tumor 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Celgene Corp.

Sponsor organisation
Celgene Corp.
Address
Route 206 And Province Line Road
City
Princeton
Postcode
08543-4000
Country
United States

Scientific contact point

Organisation
Celgene Corp.
Contact name
GSM-CT

Public contact point

Organisation
Celgene Corp.
Contact name
GSM-CT

Locations

3 EU/EEA countries · 11 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ended 16 4
Italy Ended 12 3
Spain Ended 20 4
Rest of world
Australia, Canada, Argentina, Mexico, Chile, United States
101

Investigational sites

France

4 sites · Ended
Institut Gustave Roussy
Medical Oncology, 114 Rue Edouard Vaillant, 94800, Villejuif
Institut Curie
Service d’Oncologie médicale 4/Unité d’Investigation Clinique, 26 Rue D Ulm, 75005, Paris
Institut Claudius Regaud
Medical Oncology, 1 Avenue Irene Joliot Curie, 31100, Toulouse
Institut Paoli-Calmettes
Hopital de jour médical/Unité d’Evaluation Thérapeutique en Onco-Hématologie (EOTH), 232 Boulevard De Sainte Marguerite, Bp 156, Marseille

Italy

3 sites · Ended
Istituto Oncologico Veneto
Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche, Via Gattamelata 64, 35128, Padova
Humanitas Research Hospital
Operative unit of Oncology and Hematology, Via Alessandro Manzoni 56, 20089, Rozzano
Istituto Di Candiolo Fondazione Del Piemonte Per Loncologia IRCCS
Medical Oncology, Strada Provinciale 142 Orba Km 3,95, 10060, Candiolo

Spain

4 sites · Ended
University Hospital Virgen Del Rocio S.L.
Oncologia Medica, Avenida De Manuel Siurot S/n, 41013, Sevilla
Hospital Universitario Ramon Y Cajal
Oncologia Medica, Carretera Del Colmenar Viejo Km 9 100, Por El Pardo, Madrid
Hospital Universitario 12 De Octubre
Oncologia Medica, Bloque D, Avenida De Cordoba S/n, Madrid
Hospital Clinic De Barcelona
ICMHO. Oncologia Medica, Calle Villarroel 170, 08036, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2023-09-27 2023-10-12 2024-07-18
Italy 2023-10-12 2023-11-07 2025-05-12
Spain 2023-09-15 2025-05-01 2024-09-06

Application history

7 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-03-16 Italy Acceptable
2023-07-10
2023-07-11
2 SUBSTANTIAL MODIFICATION SM-1 2023-12-05 Italy Acceptable
2024-03-22
2024-03-22
3 NON SUBSTANTIAL MODIFICATION NSM-1 2024-04-15 Italy Acceptable
2024-03-22
2024-04-15
4 NON SUBSTANTIAL MODIFICATION NSM-2 2024-09-23 Italy Acceptable
2024-03-22
2024-09-23
5 SUBSTANTIAL MODIFICATION SM-2 2024-10-24 Italy Acceptable
2024-11-25
2024-11-27
6 NON SUBSTANTIAL MODIFICATION NSM-4 2025-02-03 Acceptable
2024-11-25
2025-02-03
7 NON SUBSTANTIAL MODIFICATION NSM-5 2025-02-06 Italy Acceptable
2024-11-25
2025-02-06